GSK (LON:GSK) Stock Crosses Above 200-Day Moving Average – Here’s Why

Shares of GSK plc (LON:GSK) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,413.02 ($19.00) and traded as high as GBX 1,445.50 ($19.44). GSK shares last traded at GBX 1,436.16 ($19.31), with a volume of 26,820,320 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on GSK shares. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Friday, March 28th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of GBX 1,862.50 ($25.05).

GSK Trading Up 0.1%

The stock has a market cap of £58.28 billion, a PE ratio of 23.20, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a fifty day moving average price of GBX 1,428.18 and a 200 day moving average price of GBX 1,413.02.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities analysts expect that GSK plc will post 175.980975 EPS for the current year.

Insider Buying and Selling

In related news, insider Emma Walmsley sold 5,473 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.49), for a total transaction of £79,303.77 ($106,648.43). 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.